A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Profici
To compare maintenance treatment with sacituzumab tirumotecan plus pembrolizumab to pembrolizumab alone with respect to PFS per RECIST 1.1 as assessed by BICR in participants with pMMR primary advanced or recurrent endometrial cancer To compare maintenance treatment with sacituzumab tirumotecan plus pembrolizumab to pembrolizumab alone with respect to OS in participants with pMMR primary advanced or recurrent endometrial cancer To evaluate maintenance treatment with sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab alone with respect to PFS2, as assessed by investigator, in participants with medium + high TROP2 expressing tumors and all participants with pMMR primary advanced or recurrent endometrial cancer To evaluate the safety and tolerability of maintenance treatment with sacituzumab tirumotecan plus pembrolizumab in participants with pMMR primary advanced or recurrent endometrial cancer To compare maintenance treatment with sacituzumab tirumotecan plus pembrolizumab to pembrolizumab alone with respect to mean change from baseline in HRQoL using the EORTC QLQ-C30 in participants with pMMR primary advanced or recurrent endometrial cancer